CVE:HEM Hemostemix (HEM) Stock Price, News & Analysis C$0.04 -0.01 (-11.11%) (As of 07/26/2024 05:27 PM ET) Add Compare Share Share Today's RangeC$0.04▼C$0.0550-Day RangeC$0.04▼C$0.0752-Week RangeC$0.04▼C$0.18Volume23,000 shsAverage Volume62,854 shsMarket CapitalizationC$3.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesInsider TradesStock AnalysisChartHeadlinesInsider Trades Get Hemostemix alerts: Email Address Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About Hemostemix Stock (CVE:HEM)Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.Read More HEM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEM Stock News HeadlinesJuly 24 at 11:52 AM | theglobeandmail.comClosing Bell: Hemostemix Inc flat on Monday (HEM)July 21, 2024 | americanbankingnews.comHemostemix (CVE:HEM) Hits New 1-Year Low at $0.04July 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 2, 2024 | finance.yahoo.comGlobal Angioplasty Balloons and Stents Market to Exhibit Substantial Growth at a CAGR of ~4% by 2030 | DelveInsightMarch 7, 2024 | finanznachrichten.deHemostemix Inc.: Hemostemix Announces Engagement of Oak Hill Asset Management Inc.March 7, 2024 | finance.yahoo.comHemostemix Announces Engagement of Oak Hill Asset Management Inc.February 20, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (HEM)February 19, 2024 | theglobeandmail.comHemostemix: Top 10 Undervalued Biotechnology Industry Stocks (HEM)July 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.February 6, 2024 | finance.yahoo.comHemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental SciencesJanuary 19, 2024 | morningstar.comHemostemix Inc HMTXFOctober 30, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseOctober 30, 2023 | finance.yahoo.comHemostemix's 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart DiseaseOctober 20, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc down on Thursday (HEM)August 29, 2023 | finance.yahoo.comHemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant ApplicationsAugust 8, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Friday (HEM)June 28, 2023 | finanznachrichten.deHemostemix Inc.: Hemostemix Closes $403,539 of the Unit Private PlacementJune 28, 2023 | theglobeandmail.comClosing Bell: Hemostemix Inc up on Tuesday (HEM)See More Headlines Receive HEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:HEM CUSIPN/A CIKN/A Webwww.hemostemix.com Phone+1-403-3409207FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-2,500,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-374.39% Debt Debt-to-Equity RatioN/A Current Ratio0.11 Quick Ratio0.48 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow10.77 Book ValueC($0.09) per share Price / Book-0.44Miscellaneous Outstanding Shares87,120,000Free FloatN/AMarket CapC$3.48 million OptionableNot Optionable Beta0.62 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Thomas A. Smeenk B.A. (Age 62)BA Hons, Co-Founder, President, CEO & Director Comp: $308kMs. Christina Wu CPAInterim Chief Financial OfficerPeter PavlinVice President of OperationsDr. Fraser C. Henderson Sr.M.D., Chief Medical OfficerKey CompetitorsAntibe TherapeuticsTSE:ATEAptose BiosciencesTSE:APSResverlogixTSE:RVXIMVTSE:IMVSirona BiochemCVE:SBMView All CompetitorsInsidersThomas SmeenkBought 10,000 shares on 6/25/2024Total: C$400.00 ($0.04/share)Thomas SmeenkBought 20,000 shares on 12/14/2023Total: C$1,400.00 ($0.07/share)Thomas SmeenkBought 13,000 shares on 12/5/2023Total: C$910.00 ($0.07/share)Thomas SmeenkBought 25,000 shares on 11/7/2023Total: C$1,750.00 ($0.07/share)View All Insider Transactions HEM Stock Analysis - Frequently Asked Questions How have HEM shares performed this year? Hemostemix's stock was trading at C$0.07 at the beginning of 2024. Since then, HEM stock has decreased by 42.9% and is now trading at C$0.04. View the best growth stocks for 2024 here. How do I buy shares of Hemostemix? Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of Hemostemix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Gene Biotherapeutics (CRXM), Camber Energy (CEI), Auxly Cannabis Group (CBWTF), Cannabis Science (CBIS) and Beazer Homes USA (BZH). This page (CVE:HEM) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemostemix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemostemix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.